Sprix Approved for Moderate-to-Severe Pain

A non-narcotic nasal spray
By Scott Roberts
HealthDay Reporter

MONDAY, May 17 (HealthDay News) -- Roxro Pharma's Sprix (ketorolac tromethamine) nasal spray has been approved by the U.S. Food and Drug Administration for the short-term treatment of moderate to moderately severe pain, the manufacturer said Monday in a news release.

The nasal spray contains the non-steroidal anti-inflammatory drug (NSAID) ketorolac. The non-narcotic medication minimizes the chances for abuse and eliminates side effects associated with narcotic pain relievers, the drug maker said.

The drug should not be used for longer than five days. Potential side effects may include peptic ulcers or gastrointestinal bleeding, and the drug shouldn't be used in people who already have these conditions, a high risk of bleeding, or advanced renal failure, the company said.

Roxro is based in Menlo Park, Calif.

More information

The U.S. National Library of Medicine has more about pain relievers.

Copyright © 2010 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Debunking Three Rape Myths
Journal of Forensic Nursing, October/December 2014
Expires: 12/31/2016 CE:2.5 $24.95


Drug updates and approvals: 2014 in review
The Nurse Practitioner, 13December 2014
Expires: 12/31/2016 CE:3 $27.95


Can Food Processing Enhance Cancer Protection?
Nutrition Today, September/October 2014
Expires: 10/31/2016 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events